| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 11, 2004
From the Departments of Surgery (R.Ö., M.B., A.E., A.F., J.M., S.T., E.C., A.V.G.-S., A.L., L.E.O., K.Y., F.H.B.) and Medicine (A.E., A.U.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; Department of Surgery, Innsbruck Medical University, Innsbruck, Austria (R.Ö.); and Gulbenkian Institute for Science, Oeiras, Portugal (M.P.S.). * To whom correspondence should be addressed. E-mail: fritz_bach{at}hms.harvard.edu,.
Background--Bilirubin, a natural product of heme catabolism by heme oxygenases, was considered a toxic waste product until 1987, when its antioxidant potential was recognized. On the basis of observations that oxidative stress is a potent trigger in vascular proliferative responses, that heme oxygenase-1 is antiatherogenic, and that several studies now show that individuals with high-normal or supranormal levels of plasma bilirubin have a lesser incidence of atherosclerosis-related diseases, we hypothesized that bilirubin would have salutary effects on preventing intimal hyperplasia after balloon injury. Methods and Results--We found less balloon injury-induced neointima formation in hyperbilirubinemic Gunn rats and in wild-type rats treated with biliverdin, the precursor of bilirubin, than in controls. In vitro, bilirubin and biliverdin inhibited serum-driven smooth muscle cell cycle progression at the G1 phase via inhibition of the mitogen-activated protein kinase signal transduction pathways and inhibition of phosphorylation of the retinoblastoma tumor suppressor protein. Conclusions--Bilirubin and biliverdin might be potential therapeutics in vascular proliferative disorders.
Revised on April 25, 2005
Accepted on April 27, 2005
Bilirubin. A Natural Inhibitor of Vascular Smooth Muscle Cell Proliferation
Robert Öllinger MD*,
Related Article:
Circulation 2005 112: 935.
This article has been cited by other articles:
![]() |
B. Rantner, B. Kollerits, M. Anderwald-Stadler, P. Klein-Weigel, I. Gruber, A. Gehringer, M. Haak, M. Schnapka-Kopf, G. Fraedrich, and F. Kronenberg Association between the UGT1A1 TA-Repeat Polymorphism and Bilirubin Concentration in Patients with Intermittent Claudication: Results from the CAVASIC Study Clin. Chem., May 1, 2008; 54(5): 851 - 857. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Abraham and A. Kappas Pharmacological and Clinical Aspects of Heme Oxygenase Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Perlstein, R. L. Pande, J. A. Beckman, and M. A. Creager Serum Total Bilirubin Level and Prevalent Lower-Extremity Peripheral Arterial Disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004 Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 166 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hill-Kapturczak and A. Agarwal Haem oxygenase-1--a culprit in vascular and renal damage? Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1495 - 1499. [Full Text] [PDF] |
||||
![]() |
G. Kronke, A. Kadl, E. Ikonomu, S. Bluml, A. Furnkranz, I. J. Sarembock, V. N. Bochkov, M. Exner, B. R. Binder, and N. Leitinger Expression of Heme Oxygenase-1 in Human Vascular Cells Is Regulated by Peroxisome Proliferator-Activated Receptors Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1276 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-L. Levonen, M. Inkala, T. Heikura, S. Jauhiainen, H.-K. Jyrkkanen, E. Kansanen, K. Maatta, E. Romppanen, P. Turunen, J. Rutanen, et al. Nrf2 Gene Transfer Induces Antioxidant Enzymes and Suppresses Smooth Muscle Cell Growth In Vitro and Reduces Oxidative Stress in Rabbit Aorta In Vivo Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 741 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-m. Liu, M. A. Azam, K. J. Peyton, D. Ensenat, A. N. Keswani, H. Wang, and W. Durante Butylated hydroxyanisole stimulates heme oxygenase-1 gene expression and inhibits neointima formation in rat arteries Cardiovasc Res, April 1, 2007; 74(1): 169 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stocker and M. A. Perrella Heme Oxygenase-1: A Novel Drug Target for Atherosclerotic Diseases? Circulation, November 14, 2006; 114(20): 2178 - 2189. [Full Text] [PDF] |
||||
![]() |
J.-P. Lin, C. J. O'Donnell, J. P. Schwaiger, L. A. Cupples, A. Lingenhel, S. C. Hunt, S. Yang, and F. Kronenberg Association Between the UGT1A1*28 Allele, Bilirubin Levels, and Coronary Heart Disease in the Framingham Heart Study Circulation, October 3, 2006; 114(14): 1476 - 1481. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Ryter, J. Alam, and A. M. K. Choi Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications Physiol Rev, April 1, 2006; 86(2): 583 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Yasuda, S Okinaga, M Yamaya, T Ohrui, M Higuchi, M Shinkawa, S Itabashi, K Nakayama, M Asada, A Kikuchi, et al. Association of susceptibility to the development of pneumonia in the older Japanese population with haem oxygenase-1 gene promoter polymorphism. J. Med. Genet., April 1, 2006; 43(4): e17 - e17. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Sarady-Andrews, F. Liu, D. Gallo, A. Nakao, M. Overhaus, R. Ollinger, A. M. Choi, and L. E. Otterbein Biliverdin administration protects against endotoxin-induced acute lung injury in rats Am J Physiol Lung Cell Mol Physiol, December 1, 2005; 289(6): L1131 - L1137. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |